Moody Aldrich Partners LLC raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 38.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 62,339 shares of the company's stock after buying an additional 17,201 shares during the quarter. Axsome Therapeutics comprises 1.5% of Moody Aldrich Partners LLC's investment portfolio, making the stock its 16th largest position. Moody Aldrich Partners LLC owned approximately 0.13% of Axsome Therapeutics worth $7,271,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in AXSM. Assenagon Asset Management S.A. grew its position in shares of Axsome Therapeutics by 16,852.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company's stock worth $73,176,000 after buying an additional 623,717 shares during the last quarter. Boxer Capital Management LLC purchased a new position in shares of Axsome Therapeutics in the 4th quarter valued at approximately $39,767,000. Lazard Asset Management LLC lifted its stake in shares of Axsome Therapeutics by 525.7% in the 4th quarter. Lazard Asset Management LLC now owns 537,669 shares of the company's stock valued at $45,492,000 after purchasing an additional 451,737 shares during the period. Norges Bank purchased a new position in shares of Axsome Therapeutics in the 4th quarter valued at approximately $34,100,000. Finally, BVF Inc. IL lifted its stake in shares of Axsome Therapeutics by 32.7% in the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock valued at $117,444,000 after purchasing an additional 342,064 shares during the period. 81.49% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the company. Royal Bank Of Canada lowered their price objective on Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating for the company in a research note on Thursday, June 12th. Cantor Fitzgerald upgraded Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Jefferies Financial Group assumed coverage on Axsome Therapeutics in a research note on Monday, April 7th. They set a "buy" rating and a $200.00 price objective for the company. Mizuho lifted their price objective on Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. Finally, Morgan Stanley assumed coverage on Axsome Therapeutics in a research note on Thursday. They set an "overweight" rating and a $190.00 price objective for the company. One investment analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $172.33.
Read Our Latest Analysis on AXSM
Axsome Therapeutics Stock Performance
Shares of AXSM traded up $1.45 during trading hours on Friday, hitting $105.36. The stock had a trading volume of 245,787 shares, compared to its average volume of 669,187. The company has a debt-to-equity ratio of 3.48, a current ratio of 2.03 and a quick ratio of 1.96. Axsome Therapeutics, Inc. has a 12 month low of $72.21 and a 12 month high of $139.13. The firm has a market capitalization of $5.19 billion, a PE ratio of -18.26 and a beta of 0.46. The stock has a fifty day moving average price of $106.63 and a 200 day moving average price of $107.68.
Insider Buying and Selling at Axsome Therapeutics
In other news, General Counsel Hunter R. Murdock sold 6,014 shares of the company's stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $100.12, for a total value of $602,121.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark Coleman sold 3,750 shares of the company's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $105.47, for a total value of $395,512.50. Following the completion of the transaction, the director directly owned 50,387 shares of the company's stock, valued at approximately $5,314,316.89. This trade represents a 6.93% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 93,437 shares of company stock valued at $9,834,215. Company insiders own 22.30% of the company's stock.
About Axsome Therapeutics
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
